Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Contact Lenses | 12 | 2021 | 145 | 4.120 |
Why?
|
Cornea | 32 | 2023 | 1524 | 4.120 |
Why?
|
Corneal Diseases | 20 | 2022 | 636 | 4.080 |
Why?
|
Cross-Linking Reagents | 9 | 2022 | 694 | 2.960 |
Why?
|
Epithelium, Corneal | 5 | 2022 | 247 | 2.320 |
Why?
|
Keratoconus | 4 | 2023 | 121 | 2.270 |
Why?
|
Corneal Transplantation | 7 | 2023 | 386 | 1.990 |
Why?
|
Riboflavin | 6 | 2022 | 108 | 1.980 |
Why?
|
Photochemotherapy | 5 | 2018 | 807 | 1.830 |
Why?
|
Glaucoma | 8 | 2022 | 1159 | 1.790 |
Why?
|
Keratitis | 4 | 2021 | 268 | 1.490 |
Why?
|
Collagen | 6 | 2022 | 2689 | 1.460 |
Why?
|
Drug Delivery Systems | 8 | 2022 | 2219 | 1.440 |
Why?
|
Myopia | 5 | 2021 | 254 | 1.320 |
Why?
|
Corneal Stroma | 4 | 2020 | 174 | 1.290 |
Why?
|
Keratomileusis, Laser In Situ | 4 | 2015 | 88 | 1.280 |
Why?
|
Photosensitizing Agents | 7 | 2022 | 602 | 1.280 |
Why?
|
Contact Lenses, Hydrophilic | 3 | 2015 | 64 | 1.240 |
Why?
|
Corneal Topography | 5 | 2022 | 69 | 1.210 |
Why?
|
Ophthalmic Solutions | 14 | 2023 | 317 | 1.150 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 3 | 2022 | 109 | 1.100 |
Why?
|
Prostaglandins F, Synthetic | 2 | 2016 | 32 | 1.040 |
Why?
|
Myofibroblasts | 3 | 2022 | 222 | 1.000 |
Why?
|
Artificial Organs | 6 | 2017 | 204 | 0.980 |
Why?
|
Prostheses and Implants | 8 | 2022 | 1387 | 0.870 |
Why?
|
Bioprosthesis | 3 | 2015 | 596 | 0.840 |
Why?
|
Corneal Opacity | 1 | 2022 | 60 | 0.820 |
Why?
|
Intraocular Pressure | 4 | 2021 | 1270 | 0.810 |
Why?
|
Ultraviolet Rays | 6 | 2022 | 1060 | 0.810 |
Why?
|
Keratoplasty, Penetrating | 7 | 2023 | 155 | 0.770 |
Why?
|
Dry Eye Syndromes | 5 | 2023 | 386 | 0.770 |
Why?
|
Macular Degeneration | 2 | 2021 | 980 | 0.760 |
Why?
|
Retinal Neoplasms | 1 | 2022 | 144 | 0.750 |
Why?
|
Eye Diseases | 4 | 2021 | 669 | 0.730 |
Why?
|
Retinoblastoma | 1 | 2022 | 318 | 0.710 |
Why?
|
Conjunctival Diseases | 2 | 2018 | 122 | 0.700 |
Why?
|
Fluoroquinolones | 1 | 2021 | 310 | 0.690 |
Why?
|
Azepines | 1 | 2021 | 336 | 0.690 |
Why?
|
Orthokeratologic Procedures | 1 | 2018 | 6 | 0.670 |
Why?
|
Cytological Techniques | 1 | 2020 | 219 | 0.660 |
Why?
|
Macular Edema | 1 | 2022 | 359 | 0.620 |
Why?
|
Conjunctivitis, Allergic | 3 | 2022 | 130 | 0.620 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2021 | 1572 | 0.610 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2021 | 644 | 0.610 |
Why?
|
Lasers, Excimer | 3 | 2021 | 72 | 0.610 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 1 | 2018 | 87 | 0.600 |
Why?
|
Uveitis | 1 | 2020 | 375 | 0.580 |
Why?
|
Hyperemia | 1 | 2018 | 225 | 0.570 |
Why?
|
Cell Communication | 2 | 2021 | 1621 | 0.570 |
Why?
|
Fibroblasts | 3 | 2021 | 4161 | 0.560 |
Why?
|
Pharmaceutical Preparations | 2 | 2015 | 1071 | 0.560 |
Why?
|
Rose Bengal | 1 | 2016 | 116 | 0.550 |
Why?
|
Rabbits | 6 | 2021 | 4894 | 0.550 |
Why?
|
Porphyrins | 1 | 2018 | 348 | 0.540 |
Why?
|
Dexamethasone | 2 | 2021 | 1951 | 0.530 |
Why?
|
Conjunctivitis, Bacterial | 1 | 2015 | 24 | 0.520 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1157 | 0.520 |
Why?
|
Light | 2 | 2023 | 1374 | 0.510 |
Why?
|
Drug Carriers | 2 | 2021 | 693 | 0.500 |
Why?
|
Focal Infection, Dental | 1 | 2014 | 24 | 0.490 |
Why?
|
Coated Materials, Biocompatible | 1 | 2016 | 319 | 0.490 |
Why?
|
Cyclosporine | 3 | 2023 | 786 | 0.480 |
Why?
|
Visual Prosthesis | 1 | 2015 | 52 | 0.480 |
Why?
|
Prosthesis Implantation | 4 | 2013 | 642 | 0.480 |
Why?
|
Photorefractive Keratectomy | 2 | 2021 | 38 | 0.480 |
Why?
|
Fluorescein | 4 | 2023 | 171 | 0.470 |
Why?
|
Tears | 5 | 2023 | 256 | 0.460 |
Why?
|
Staphylococcal Skin Infections | 1 | 2014 | 75 | 0.460 |
Why?
|
Ophthalmology | 3 | 2015 | 508 | 0.460 |
Why?
|
Lenses, Intraocular | 1 | 2015 | 140 | 0.460 |
Why?
|
Diabetic Retinopathy | 1 | 2022 | 1210 | 0.440 |
Why?
|
Retinal Diseases | 2 | 2018 | 683 | 0.430 |
Why?
|
Biosensing Techniques | 1 | 2018 | 668 | 0.420 |
Why?
|
Econazole | 1 | 2011 | 4 | 0.410 |
Why?
|
Biocompatible Materials | 5 | 2022 | 1736 | 0.410 |
Why?
|
Dilatation, Pathologic | 3 | 2022 | 520 | 0.410 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1632 | 0.380 |
Why?
|
Postoperative Complications | 7 | 2021 | 15295 | 0.370 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2009 | 48 | 0.340 |
Why?
|
Reimbursement Mechanisms | 1 | 2015 | 670 | 0.340 |
Why?
|
Delayed-Action Preparations | 3 | 2019 | 968 | 0.340 |
Why?
|
Diagnostic Techniques, Ophthalmological | 2 | 2008 | 245 | 0.330 |
Why?
|
Administration, Topical | 4 | 2019 | 690 | 0.330 |
Why?
|
Humans | 72 | 2023 | 744343 | 0.330 |
Why?
|
Drug Approval | 1 | 2015 | 742 | 0.330 |
Why?
|
Refractive Errors | 2 | 2021 | 142 | 0.320 |
Why?
|
Candida albicans | 1 | 2011 | 394 | 0.320 |
Why?
|
Cosmetics | 1 | 2009 | 97 | 0.320 |
Why?
|
Steroids | 3 | 2022 | 930 | 0.310 |
Why?
|
Endothelial Cells | 1 | 2020 | 3479 | 0.310 |
Why?
|
Ciprofloxacin | 1 | 2009 | 315 | 0.290 |
Why?
|
Antifungal Agents | 1 | 2011 | 730 | 0.280 |
Why?
|
Wound Healing | 4 | 2022 | 2785 | 0.280 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 7181 | 0.280 |
Why?
|
Corneal Neovascularization | 2 | 2022 | 188 | 0.280 |
Why?
|
Surgical Flaps | 1 | 2015 | 1640 | 0.280 |
Why?
|
Ocular Hypertension | 2 | 2018 | 198 | 0.280 |
Why?
|
Anthropometry | 2 | 2008 | 1350 | 0.270 |
Why?
|
Cicatrix | 2 | 2022 | 764 | 0.270 |
Why?
|
Epithelial Cells | 3 | 2022 | 3690 | 0.250 |
Why?
|
Photography | 1 | 2007 | 520 | 0.240 |
Why?
|
Graft Rejection | 3 | 2014 | 4397 | 0.240 |
Why?
|
Asthenopia | 1 | 2023 | 12 | 0.230 |
Why?
|
Graft Survival | 3 | 2013 | 3737 | 0.230 |
Why?
|
Mite Infestations | 1 | 2023 | 8 | 0.230 |
Why?
|
Mites | 1 | 2023 | 43 | 0.230 |
Why?
|
Eyelashes | 1 | 2023 | 16 | 0.230 |
Why?
|
Basketball | 1 | 2003 | 49 | 0.230 |
Why?
|
Eye Infections, Parasitic | 1 | 2023 | 24 | 0.230 |
Why?
|
Blepharitis | 1 | 2023 | 36 | 0.230 |
Why?
|
Anti-Allergic Agents | 2 | 2022 | 141 | 0.220 |
Why?
|
Optic Nerve Injuries | 1 | 2003 | 150 | 0.210 |
Why?
|
Immunosuppressive Agents | 3 | 2021 | 4149 | 0.200 |
Why?
|
Prednisolone | 1 | 2022 | 334 | 0.200 |
Why?
|
Presbyopia | 1 | 2021 | 9 | 0.200 |
Why?
|
Achromobacter | 1 | 2021 | 7 | 0.200 |
Why?
|
Visual Acuity | 5 | 2021 | 2530 | 0.200 |
Why?
|
Aqueous Humor | 1 | 2021 | 161 | 0.200 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 972 | 0.200 |
Why?
|
Limit of Detection | 1 | 2021 | 265 | 0.190 |
Why?
|
Disease Models, Animal | 4 | 2023 | 18029 | 0.190 |
Why?
|
Computers | 1 | 2023 | 612 | 0.190 |
Why?
|
Organ Preservation Solutions | 1 | 2021 | 98 | 0.190 |
Why?
|
Polyhydroxyethyl Methacrylate | 2 | 2011 | 31 | 0.190 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3843 | 0.190 |
Why?
|
Staphylococcus aureus | 1 | 2009 | 1451 | 0.190 |
Why?
|
Nerve Growth Factor | 1 | 2021 | 149 | 0.180 |
Why?
|
Iron Chelating Agents | 1 | 2021 | 139 | 0.180 |
Why?
|
Corneal Ulcer | 2 | 2011 | 169 | 0.180 |
Why?
|
Eye | 2 | 2021 | 729 | 0.180 |
Why?
|
Posterior Eye Segment | 1 | 2019 | 14 | 0.180 |
Why?
|
Drug Contamination | 1 | 2021 | 147 | 0.180 |
Why?
|
Guaifenesin | 1 | 2019 | 5 | 0.180 |
Why?
|
Fuchs' Endothelial Dystrophy | 1 | 2021 | 84 | 0.170 |
Why?
|
Culture Media, Conditioned | 1 | 2020 | 537 | 0.170 |
Why?
|
Fluorescence | 1 | 2021 | 751 | 0.170 |
Why?
|
Limbus Corneae | 1 | 2021 | 144 | 0.170 |
Why?
|
Follow-Up Studies | 11 | 2022 | 39050 | 0.170 |
Why?
|
Polyglycolic Acid | 2 | 2011 | 407 | 0.160 |
Why?
|
Retrospective Studies | 12 | 2023 | 77449 | 0.160 |
Why?
|
Conjunctiva | 2 | 2021 | 494 | 0.160 |
Why?
|
Bibliometrics | 1 | 2022 | 339 | 0.160 |
Why?
|
Tight Junctions | 1 | 2020 | 311 | 0.160 |
Why?
|
Double-Blind Method | 7 | 2023 | 12026 | 0.160 |
Why?
|
Microscopy, Electron, Scanning | 2 | 2011 | 964 | 0.160 |
Why?
|
Proteomics | 2 | 2022 | 3638 | 0.150 |
Why?
|
Tissue Donors | 3 | 2021 | 2240 | 0.150 |
Why?
|
Retina | 2 | 2019 | 2616 | 0.150 |
Why?
|
Ultrasonography | 2 | 2007 | 5985 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 10943 | 0.150 |
Why?
|
United States Food and Drug Administration | 2 | 2015 | 1584 | 0.150 |
Why?
|
Prospective Studies | 16 | 2023 | 53288 | 0.150 |
Why?
|
Tensile Strength | 1 | 2018 | 335 | 0.150 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 8642 | 0.150 |
Why?
|
Medicare | 1 | 2015 | 6566 | 0.150 |
Why?
|
Middle Aged | 25 | 2023 | 213383 | 0.150 |
Why?
|
Cataract Extraction | 2 | 2015 | 481 | 0.140 |
Why?
|
Antihypertensive Agents | 2 | 2017 | 2046 | 0.140 |
Why?
|
Coculture Techniques | 1 | 2020 | 1341 | 0.140 |
Why?
|
Replantation | 1 | 2017 | 148 | 0.140 |
Why?
|
Female | 30 | 2023 | 380194 | 0.140 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2014 | 281 | 0.140 |
Why?
|
Burns, Chemical | 1 | 2018 | 159 | 0.140 |
Why?
|
Fibronectins | 1 | 2020 | 726 | 0.140 |
Why?
|
Pruritus | 2 | 2022 | 361 | 0.140 |
Why?
|
Cryopreservation | 1 | 2020 | 670 | 0.130 |
Why?
|
Fluorescent Dyes | 3 | 2021 | 1917 | 0.130 |
Why?
|
Equipment Design | 2 | 2016 | 3582 | 0.130 |
Why?
|
Male | 28 | 2023 | 350118 | 0.130 |
Why?
|
Tonometry, Ocular | 1 | 2016 | 237 | 0.130 |
Why?
|
Anterior Eye Segment | 1 | 2016 | 152 | 0.130 |
Why?
|
Prosthesis Fitting | 1 | 2015 | 74 | 0.130 |
Why?
|
Prosthesis Design | 4 | 2011 | 2110 | 0.130 |
Why?
|
Vision Disorders | 2 | 2015 | 1058 | 0.130 |
Why?
|
Inflammation | 3 | 2022 | 10638 | 0.130 |
Why?
|
Fibrosis | 1 | 2022 | 2029 | 0.130 |
Why?
|
Fluorescein Angiography | 1 | 2019 | 940 | 0.130 |
Why?
|
Lactic Acid | 2 | 2011 | 1133 | 0.130 |
Why?
|
Glaucoma, Open-Angle | 1 | 2021 | 706 | 0.130 |
Why?
|
Cell Separation | 1 | 2020 | 1751 | 0.130 |
Why?
|
beta-Lactamases | 1 | 2016 | 306 | 0.120 |
Why?
|
Animals | 10 | 2023 | 168757 | 0.120 |
Why?
|
Methylprednisolone | 1 | 2016 | 387 | 0.120 |
Why?
|
Cells, Cultured | 2 | 2020 | 19229 | 0.120 |
Why?
|
Technology, Pharmaceutical | 1 | 2014 | 84 | 0.120 |
Why?
|
Macaca fascicularis | 1 | 2016 | 915 | 0.120 |
Why?
|
Educational Measurement | 2 | 2015 | 1210 | 0.120 |
Why?
|
Collagenases | 1 | 2014 | 228 | 0.120 |
Why?
|
Propoxycaine | 1 | 2013 | 6 | 0.120 |
Why?
|
Eye Infections, Bacterial | 1 | 2016 | 235 | 0.120 |
Why?
|
Cell Differentiation | 2 | 2021 | 11483 | 0.110 |
Why?
|
Polymethyl Methacrylate | 2 | 2011 | 145 | 0.110 |
Why?
|
Device Approval | 1 | 2015 | 163 | 0.110 |
Why?
|
Drug Stability | 1 | 2013 | 291 | 0.110 |
Why?
|
Microscopy, Confocal | 2 | 2017 | 1970 | 0.110 |
Why?
|
Elasticity | 1 | 2015 | 657 | 0.110 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2013 | 170 | 0.110 |
Why?
|
Aged | 17 | 2022 | 163280 | 0.110 |
Why?
|
Escherichia coli Infections | 1 | 2016 | 532 | 0.110 |
Why?
|
Iron | 1 | 2021 | 1774 | 0.110 |
Why?
|
Sodium Channel Blockers | 1 | 2013 | 176 | 0.110 |
Why?
|
Tacrolimus | 1 | 2016 | 743 | 0.110 |
Why?
|
Tetrodotoxin | 1 | 2013 | 259 | 0.110 |
Why?
|
Benzazepines | 1 | 2014 | 326 | 0.100 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2016 | 567 | 0.100 |
Why?
|
Glucocorticoids | 1 | 2021 | 2107 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3508 | 0.100 |
Why?
|
Adult | 19 | 2022 | 214055 | 0.100 |
Why?
|
Desiccation | 1 | 2011 | 70 | 0.100 |
Why?
|
Ophthalmic Nerve | 1 | 2011 | 43 | 0.100 |
Why?
|
Anesthesia, Local | 1 | 2013 | 275 | 0.100 |
Why?
|
Eye Banks | 2 | 2021 | 38 | 0.100 |
Why?
|
Eye Infections | 1 | 2011 | 64 | 0.100 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1738 | 0.090 |
Why?
|
Refraction, Ocular | 2 | 2021 | 182 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 2 | 2018 | 1790 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1681 | 0.090 |
Why?
|
Cell Movement | 1 | 2022 | 5217 | 0.090 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2133 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.090 |
Why?
|
Spectrum Analysis, Raman | 1 | 2011 | 247 | 0.080 |
Why?
|
Titanium | 1 | 2011 | 494 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 2 | 2022 | 2038 | 0.080 |
Why?
|
Imidazoles | 1 | 2014 | 1206 | 0.080 |
Why?
|
Body Weights and Measures | 1 | 2008 | 211 | 0.080 |
Why?
|
Allergens | 1 | 2014 | 1320 | 0.070 |
Why?
|
Quality of Life | 3 | 2023 | 12804 | 0.070 |
Why?
|
Glucose | 1 | 2018 | 4397 | 0.070 |
Why?
|
Anesthetics, Local | 1 | 2013 | 985 | 0.070 |
Why?
|
United States | 4 | 2022 | 69872 | 0.070 |
Why?
|
Acute Disease | 2 | 2014 | 7149 | 0.070 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1198 | 0.070 |
Why?
|
Young Adult | 7 | 2022 | 56430 | 0.070 |
Why?
|
Clinical Competence | 2 | 2015 | 4687 | 0.070 |
Why?
|
Aged, 80 and over | 9 | 2022 | 57776 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25043 | 0.060 |
Why?
|
Escherichia coli | 1 | 2016 | 4217 | 0.060 |
Why?
|
Tomography, Optical Coherence | 1 | 2016 | 2657 | 0.060 |
Why?
|
Eye Protective Devices | 1 | 2003 | 33 | 0.060 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 2957 | 0.060 |
Why?
|
Sulfonamides | 1 | 2013 | 1938 | 0.060 |
Why?
|
Medication Adherence | 1 | 2014 | 2063 | 0.060 |
Why?
|
Microbial Sensitivity Tests | 2 | 2021 | 1877 | 0.050 |
Why?
|
Child | 4 | 2022 | 77709 | 0.050 |
Why?
|
Cell Count | 2 | 2021 | 1856 | 0.050 |
Why?
|
Risk Factors | 5 | 2022 | 72290 | 0.050 |
Why?
|
Postoperative Period | 1 | 2007 | 1842 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2023 | 63114 | 0.050 |
Why?
|
Erythema | 1 | 2023 | 257 | 0.050 |
Why?
|
Rodentia | 1 | 2023 | 261 | 0.050 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2021 | 24 | 0.050 |
Why?
|
Decision Making | 1 | 2015 | 3887 | 0.050 |
Why?
|
Internship and Residency | 2 | 2015 | 5788 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2007 | 2373 | 0.050 |
Why?
|
Reference Values | 1 | 2008 | 4982 | 0.050 |
Why?
|
Pyrimidines | 1 | 2013 | 2942 | 0.050 |
Why?
|
Meibomian Glands | 1 | 2020 | 85 | 0.050 |
Why?
|
Adolescent | 6 | 2021 | 85781 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2011 | 2725 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 5751 | 0.040 |
Why?
|
DNA, Ribosomal | 1 | 2021 | 290 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 3923 | 0.040 |
Why?
|
Bacteriological Techniques | 1 | 2021 | 277 | 0.040 |
Why?
|
Expectorants | 1 | 2019 | 16 | 0.040 |
Why?
|
Donor Selection | 1 | 2021 | 201 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 9959 | 0.040 |
Why?
|
Eyelid Diseases | 1 | 2020 | 155 | 0.040 |
Why?
|
Drug Compounding | 1 | 2019 | 242 | 0.040 |
Why?
|
Keratoconjunctivitis Sicca | 1 | 2017 | 27 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5137 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2021 | 369 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 302 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2018 | 95 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 954 | 0.040 |
Why?
|
Staining and Labeling | 1 | 2021 | 1100 | 0.040 |
Why?
|
Benzimidazoles | 1 | 2022 | 850 | 0.040 |
Why?
|
Drug Implants | 1 | 2017 | 244 | 0.030 |
Why?
|
Intravitreal Injections | 1 | 2017 | 344 | 0.030 |
Why?
|
Water | 1 | 2021 | 1395 | 0.030 |
Why?
|
Time Factors | 3 | 2013 | 40075 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12959 | 0.030 |
Why?
|
Piperidines | 1 | 2022 | 1602 | 0.030 |
Why?
|
Anesthetics, Combined | 1 | 2013 | 40 | 0.030 |
Why?
|
Cohort Studies | 2 | 2013 | 40561 | 0.030 |
Why?
|
Quaternary Ammonium Compounds | 1 | 2013 | 205 | 0.030 |
Why?
|
Virulence | 1 | 2016 | 1333 | 0.030 |
Why?
|
Equipment Contamination | 1 | 2013 | 185 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2007 | 19905 | 0.030 |
Why?
|
Membranes | 1 | 2012 | 173 | 0.030 |
Why?
|
Indazoles | 1 | 2013 | 289 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 3913 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 941 | 0.020 |
Why?
|
Phagocytosis | 1 | 2016 | 1539 | 0.020 |
Why?
|
Focus Groups | 1 | 2013 | 1321 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2014 | 956 | 0.020 |
Why?
|
Nervous System | 1 | 2011 | 554 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1590 | 0.020 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2009 | 349 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 4420 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8324 | 0.020 |
Why?
|
Reoperation | 1 | 2015 | 4201 | 0.020 |
Why?
|
Immune System | 1 | 2011 | 805 | 0.020 |
Why?
|
Glaucoma Drainage Implants | 1 | 2006 | 116 | 0.020 |
Why?
|
Trabeculectomy | 1 | 2006 | 160 | 0.020 |
Why?
|
Prevalence | 1 | 2021 | 15226 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 20947 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2009 | 1683 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3022 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7322 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 8301 | 0.010 |
Why?
|
Feedback | 1 | 2005 | 795 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7913 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3396 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15997 | 0.010 |
Why?
|
Teaching | 1 | 2005 | 1174 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2009 | 5391 | 0.010 |
Why?
|
Rats | 1 | 2013 | 24260 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2005 | 2291 | 0.010 |
Why?
|
Curriculum | 1 | 2005 | 3605 | 0.010 |
Why?
|
Databases, Factual | 1 | 2005 | 7729 | 0.010 |
Why?
|